Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316Coleen K. Cunningham, John L. Sullivan, Brigitte Bazin et al.|The Journal of Infectious Diseases|2002Cited by 136
Maternal toxicity and pregnancy complications in human immunodeficiency virus–infected women receiving antiretroviral therapy: PACTG 316D. Heather Watts, Coleen K. Cunningham, Rajalakshmi Balasubramanian et al.|American Journal of Obstetrics and Gynecology|2004Cited by 99
Predose Infant Nevirapine Concentration With the Two-Dose Intrapartum Neonatal Nevirapine Regimen: Association With Timing of Maternal Intrapartum Nevirapine DoseMark Mirochnick, John L. Sullivan, Alejandro Dorenbaum et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2003Cited by 44
A Recombinant Antibody to Siglec-8 Shows Selective ADCC Activity Against Mast Cells from Systemic Mastocytosis PatientsRustom Falahati, Jason Gotlib, Diane S. Lidke et al.|Blood|2015Cited by 4